LPL Financial’s Cellectar Biosciences CLRB Stock Holding History

LPL Financial’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-47	Closed	-$13K	–	4358
2021 Q3	$13K	Buy	+47	New	+$14.3K	﹤0.01%	4308

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial's CLRB Position: Q4 2021 in Review

LPL Financial sold out of Cellectar Biosciences (CLRB) in Q4 2021, closing a stake of 47 shares — an estimated $13K sold.

LPL Financial first reported a position in CLRB in Q3 2021 and held it in 1 quarter. The position peaked at $13K in Q3 2021. 41 funds tracked by Wall St. Rank hold CLRB as of Q4 2021.

LPL Financial reported no remaining Cellectar Biosciences position as of Q4 2021 after selling out during the quarter.
LPL Financial sold 47 Cellectar Biosciences shares in Q4 2021, an estimated $13K.
LPL Financial first reported a position in Cellectar Biosciences in Q3 2021 and held it in 1 quarter.
LPL Financial's Cellectar Biosciences position peaked at $13K in Q3 2021.
41 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2021.

Based on LPL Financial's 13F filing for Q4 2021, filed 14 Feb 2022.